Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$409.59
pos +0.00
+0.00%
Today's Range: 405.80 - 411.31 | BIIB Avg Daily Volume: 1,805,300
Last Update: 02/27/15 - 4:00 PM EST
Volume: 0
YTD Performance: 20.66%
Open: $0.00
Previous Close: $410.10
52 Week Range: $272.02 - $412.02
Oustanding Shares: 234,614,474
Market Cap: 96,215,395,787
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 12 11 11
Moderate Buy 1 1 1 1
Hold 4 4 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.53 1.53 1.65 1.65
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 33.15
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
33.15 33.10 26.52
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
34.33% 19.12% 251.88%
GROWTH 12 Mo 3 Yr CAGR
Revenue 46.50 0.92 0.24
Net Income 57.90 1.32 0.32
EPS 58.30 1.44 0.34
Earnings for BIIB:
EBITDA 3.41B
Revenue 8.51B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $3.96 $4.09 $16.79 $20.10
Number of Analysts 1 1 2 2
High Estimate $3.96 $4.09 $16.81 $20.56
Low Estimate $3.96 $4.09 $16.77 $19.65
Prior Year $2.45 $3.49 $13.79 $16.79
Growth Rate (Year over Year) 61.63% 17.19% 21.75% 19.74%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Feb 19, 2015 | 11:02 AM EST

Watch this leadership group that's been lagging.

By

Bret Jensen

 | Feb 2, 2015 | 10:01 AM EST
Trading in February has commenced and indices started up, but have already given all of their early gains. Americans boosted their savings in December and cut spending by the largest amount in five years.

bullishBiogen Idec numbers boosted at Nomura

Jan 30, 2015 | 7:29 AM EST

Shares of BIIB now seen reaching $401, according to Nomura. Estimates also upped, given the company's new guidance. Neutral rating.

By

Doug Kass

 | Jan 28, 2015 | 7:10 AM EST
U.S. futures higher: S&P 500 futures +4 and Nasdaq futures are 37 handles higher -- thanks to Apple's (AAPL) blow-out quarter. European markets have flat-lined. Japan's Nikkei 225 is +0.15%. Little in the news. Within the index, energy and tech lagged, while staples health care and telecoms outperformed. Nintendo reported weak results while Komatsu's performance was good.  The Chinese market is down 1.41% on the back of reports on another crackdown on margin trading. Every sub group was in the red. Gold is down by $1/oz and crude oil is -$0.70.(I was stopped out of my USO long for a $0.18 gain yesterday). Natural gas is down by 2.7% to $2.90  and copper is up +0.5%. The U.S. dollar is +0.08% and the euro is down -0.23%. The yield on the 10-year U.S. Treasury note is down by two basis points to 1.795% (a lot of volatility has entered this market in the last few days- just like currencies). Sovereign-debt yields in Greece are rising big time.   There is no clea
By

Jim Cramer

 | Jan 26, 2015 | 3:58 PM EST

These are surefire indications of a bountiful tape.

By

Jim Cramer

 | Jan 15, 2015 | 3:40 PM EST

Use the overall weakness to pick up the America First stocks.

By

Timothy Collins

 | Jan 8, 2015 | 10:09 AM EST
Do you need to pick one name?

bullishBiogen Idec rated new Overweight at Barclays

Jan 6, 2015 | 7:49 AM EST

Coverage of BIIB was started with an Overweight rating, Barclays said. $425 price target. Company has a solid pipeline and Tecfidera should drive growth. 

By

Carolyn Boroden

 | Dec 29, 2014 | 9:00 AM EST

Here's how to trade some key price relationships.

By

Jim Cramer

 | Dec 22, 2014 | 7:00 AM EST

Throughout this historic run, four groups have consistently led the market.

Reports on Tuesday. I am getting a little concerned on how the 2015 guidance will come in....
Soz doing some more good stuff on retail today-- I loved the JCP piece.. Remember you can ...
Despite a big upgrade from Credit Suisse(from Neutral to Outperform)FDX is relatively...
The Market Vectors Gold Miners ETF (GDX) chart continues to exhibit characteristics of a c...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.